Skip to main content
Premium Trial:

Request an Annual Quote

PanVera President to Pull Double Duty as Head of Aurora Biosciences

NEW YORK, March 14 - Vertex Pharmaceuticals on Thursday has appointed Michael Wokasch president of its Aurora Biosciences unit.

 

Wokasch is already president of another Vertex subsidiary, PanVera, and will retain that role. At Aurora, he replaces Harry Stylli, who left the firm.

 

Wokasch will help the company broaden its customer base and expand customer relationships, said Vertex chairman and CEO Joshua Boger in a statement.

 

Vertex acquired Aurora last year in order to expand its drug discovery in G-protein coupled receptor and ion channel genes.

 

PanVera is a recombinant protein manufacturer that Aurora snapped up in 2000 for about $36 million. Wokasch became PanVera's president in July 2001.

 

Prior to that, he was CEO and president of startup Gala Design.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.